Cancer stem cells in prostate cancer chemoresistance

Current Cancer Drug Targets

Volumn 14, Issue 3, 2014, Pages 225-240

  Ni, Jie ^a,b   Cozzi, Paul ^a,b   Hao, Jingli ^a,b   Duan, Wei ^c   Graham, Peter ^a,b   Kearsley, John ^a,b   Li, Yong ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Cancer stem cell; Castration resistant prostate cancer; Chemoresistance; EMT; Prostate cancer; Treatment

Indexed keywords

ABC TRANSPORTER; ANDROGEN RECEPTOR; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CELL NUCLEUS RECEPTOR; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; KRUPPEL LIKE FACTOR 4; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MYC PROTEIN; NESTIN; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STEM CELL FACTOR; TESTICULAR NUCLEAR RECEPTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

AKT KINASE ASSAY; APOPTOSIS; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SELECTION; CHEMOSENSITIVITY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; IMMUNE DEFICIENCY; METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; PTEN GENE; REVIEW; UPREGULATION; WNT SIGNALING PATHWAY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; MALE; PATHOLOGY; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS;

EID: 84903748693     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140328152459     Document Type: Review

References (155)

1. Beltran, H.; Beer, T.M.; Carducci, M.A.; de Bono, J.; Gleave, M.; Hussain, M.; Kelly, W.K.; Saad, F.; Sternberg, C.; Tagawa, S.T.; Tannock, I.F. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur. Urol. 2011, 60 (2), 279-290.
2. Logothetis, C.J. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Williston Park), 2002, 16 (6 Suppl 6), 63-72.
3. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; Lara, P.N., Jr.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M.C.; Small, E.J.; Raghavan, D.; Crawford, E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351 (15), 1513-1520.
4. Berthold, D.R.; Pond, G.R.; Soban, F.; de Wit, R.; Eisenberger, M.; Tannock, I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 2008, 26 (2), 242-245.
5. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Theodore, C.; James, N.D.; Turesson, I.; Rosenthal, M.A.; Eisenberger, M.A.; Investigators, T.A.X. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351 (15), 1502-1512.
6. Kantoff, P.W.; Halabi, S.; Conaway, M.; Picus, J.; Kirshner, J.; Hars, V.; Trump, D.; Winer, E.P.; Vogelzang, N.J. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 1999, 17 (8), 2506-2513.
7. de Bono, J.S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, L.; Roessner, M.; Gupta, S.; Sartor, A.O.; Investigators, T. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376 (9747), 1147-1154.
8. Sternberg, C.N.; Dumez, H.; Van Poppel, H.; Skoneczna, I.; Sella, A.; Daugaard, G.; Gil, T.; Graham, J.; Carpentier, P.; Calabro, F.; Collette, L.; Lacombe, D.; EORTC Genitourinary Tract Cancer Group. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann. Oncol. 2009, 20 (7), 1264-1269.
9. Ni, J.; Cozzi, P.J.; Duan, W.; Shigdar, S.; Graham, P.H.; Kearsley, J.H.; Li, Y. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 2012, 31, (3- 4), 779-791.
10. O'Brien, C.A.; Kreso, A.; Dick, J.E. Cancer stem cells in solid tumors: an overview. Semin. Radiat. Oncol. 2009, 19 (2), 71-77.
11. Clarke, M.F.; Fuller, M. Stem cells and cancer: two faces of eve. Cell 2006, 124 (6), 1111-1115.
12. Gupta, P.B.; Chaffer, C.L.; Weinberg, R.A. Cancer stem cells: mirage or reality? Nat. Med. 2009, 15 (9), 1010-1012.
13. Hao, J.; Madigan, M.C.; Khatri, A.; Power, C.A.; Hung, T.T.; Beretov, J.; Chang, L.; Xiao, W.; Cozzi, P.J.; Graham, P.H.; Kearsley, J.H.; Li, Y. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One 2012, 7 (8), e40716.
14. McCubrey, J.A.; Abrams, S.L.; Stadelman, K.; Chappell, W.H.; Lahair, M.; Ferland, R.A.; Steelman, L.S. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv. Enzyme Regul. 2010, 50 (1), 285-307.
15. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414 (6859), 105-111.
16. Jordan, C.T.; Guzman, M.L.; Noble, M. Cancer stem cells. N. Engl. J. Med. 2006, 355 (12), 1253-1261.
17. Visvader, J.E. Cells of origin in cancer. Nature 2011, 469 (7330), 314-322.
18. Chaffer, C.L.; Brueckmann, I.; Scheel, C.; Kaestli, A.J.; Wiggins, P.A.; Rodrigues, L.O.; Brooks, M.; Reinhardt, F.; Su, Y.; Polyak, K.; Arendt, L.M.; Kuperwasser, C.; Bierie, B.; Weinberg, R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (19), 7950-7955.
19. Shigdar, S.; Li, Y.; Bhattacharya, S.; O'Connor, M.; Pu, C.; Lin, J.; Wang, T.; Xiang, D.; Kong, L.; Wei, M.Q.; Zhu, Y.; Zhou, S.; Duan, W. Inflammation and cancer stem cells. Cancer Lett. 2014, 345 (2), 271-278.
20. Iliopoulos, D.; Hirsch, H.A.; Wang, G.; Struhl, K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (4), 1397-1402.
21. Chaffer, C.L.; Marjanovic, N.D.; Lee, T.; Bell, G.; Kleer, C.G.; Reinhardt, F.; D'Alessio, A.C.; Young, R.A.; Weinberg, R.A. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013, 154 (1), 61-74.
22. Nagle, R.B.; Ahmann, F.R.; McDaniel, K.M.; Paquin, M.L.; Clark, V.A.; Celniker, A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res. 1987, 47 (1), 281-286.
23. Gu, G.; Yuan, J.; Wills, M.; Kasper, S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007, 67 (10), 4807-4815.
24. Li, Y.; Cozzi, P.J.; Russell, P.J. Promising tumor-associated antigens for future prostate cancer therapy. Med. Res. Rev. 2010, 30 (1), 67-101.
25. Li, H.; Chen, X.; Calhoun-Davis, T.; Claypool, K.; Tang, D.G. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res. 2008, 68 (6), 1820-1825.
26. Li, H.; Jiang, M.; Honorio, S.; Patrawala, L.; Jeter, C.R.; Calhoun-Davis, T.; Hayward, S.W.; Tang, D.G. Methodologies in assaying prostate cancer stem cells. Methods Mol. Biol. 2009, 568, 85-138.
27. Lang, S.H.; Frame, F.M.; Collins, A.T. Prostate cancer stem cells. J. Pathol. 2009, 217 (2), 299-306.
28. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65 (23), 10946-10951.
29. Collins, A.T.; Maitland, N.J. Prostate cancer stem cells. Eur. J. Cancer 2006, 42 (9), 1213-1218.
30. Maitland, N.J.; Collins, A.T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 2008, 26 (17), 2862-2870.
31. Patrawala, L.; Calhoun-Davis, T.; Schneider-Broussard, R.; Tang, D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007, 67 (14), 6796-6805.
32. Rowehl, R.A.; Crawford, H.; Dufour, A.; Ju, J.; Botchkina, G.I. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genomics Proteomics 2008, 5 (6), 301-310.
33. Dubrovska, A.; Kim, S.; Salamone, R.J.; Walker, J.R.; Maira, S.M.; Garcia-Echeverria, C.; Schultz, P.G.; Reddy, V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (1), 268-273.
34. Hurt, E.M.; Kawasaki, B.T.; Klarmann, G.J.; Thomas, S.B.; Farrar, W.L. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 2008, 98 (4), 756-765.
35. Qin, J.; Liu, X.; Laffin, B.; Chen, X.; Choy, G.; Jeter, C.R.; Calhoun-Davis, T.; Li, H.; Palapattu, G.S.; Pang, S.; Lin, K.; Huang, J.; Ivanov, I.; Li, W.; Suraneni, M.V.; Tang, D.G. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012, 10 (5), 556-569.
36. Domingo-Domenech, J.; Vidal, S.J.; Rodriguez-Bravo, V.; Castillo-Martin, M.; Quinn, S.A.; Rodriguez-Barrueco, R.; Bonal, D.M.; Charytonowicz, E.; Gladoun, N.; de la Iglesia-Vicente, J.; Petrylak, D.P.; Benson, M.C.; Silva, J.M.; Cordon-Cardo, C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumorinitiating cells. Cancer Cell 2012, 22 (3), 373-388.
37. Ponta, H.; Sherman, L.; Herrlich, P.A., CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4 (1), 33-45.
38. Naor, D.; Wallach-Dayan, S.B.; Zahalka, M.A.; Sionov, R.V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin. Cancer Biol. 2008, 18 (4), 260-267.
39. Gunthert, U.; Hofmann, M.; Rudy, W.; Reber, S.; Zoller, M.; Haussmann, I.; Matzku, S.; Wenzel, A.; Ponta, H.; Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65 (1), 13-24.
40. Charpin, C.; Secq, V.; Giusiano, S.; Carpentier, S.; Andrac, L.; Lavaut, M.N.; Allasia, C.; Bonnier, P.; Garcia, S. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int. J. Cancer 2009, 124 (9), 2124-2134.
41. Ween, M.P.; Oehler, M.K.; Ricciardelli, C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int. J. Mol. Sci. 2011, 12 (2), 1009-1029.
42. Hebbard, L.; Steffen, A.; Zawadzki, V.; Fieber, C.; Howells, N.; Moll, J.; Ponta, H.; Hofmann, M.; Sleeman, J. CD44 expression and regulation during mammary gland development and function. J. Cell Sci. 2000, 113 (Pt 14), 2619-2630.
43. Yang, Y.M.; Chang, J.W. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 2008, 26 (7), 725-733.
44. Bidlingmaier, S.; Zhu, X.; Liu, B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J. Mol. Med. (Berl), 2008, 86 (9), 1025-1032.
45. Coskun, V.; Wu, H.; Blanchi, B.; Tsao, S.; Kim, K.; Zhao, J.; Biancotti, J.C.; Hutnick, L.; Krueger, R.C., Jr.; Fan, G.; de Vellis, J.; Sun, Y.E. CD133+ neural stem cells in the ependyma of mammalian postnatal forebrain. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (3), 1026-1031.
46. Pellacani, D.; Oldridge, E.E.; Collins, A.T.; Maitland, N.J. Prominin-1 (CD133) Expression in the prostate and prostate cancer: A marker for quiescent stem cells. Adv. Exp. Med. Biol. 2013, 777, 167-184.
47. Richardson, G.D.; Robson, C.N.; Lang, S.H.; Neal, D.E.; Maitland, N.J.; Collins, A.T. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 2004, 117 (Pt 16), 3539-3545.
48. Vander Griend, D.J.; Karthaus, W.L.; Dalrymple, S.; Meeker, A.; DeMarzo, A.M.; Isaacs, J.T. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008, 68 (23), 9703-9711.
49. Pfeiffer, M.J.; Schalken, J.A. Stem cell characteristics in prostate cancer cell lines. Eur. Urol. 2010, 57 (2), 246-254.
50. Kemper, K.; Sprick, M.R.; de Bree, M.; Scopelliti, A.; Vermeulen, L.; Hoek, M.; Zeilstra, J.; Pals, S.T.; Mehmet, H.; Stassi, G.; Medema, J.P. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010, 70 (2), 719-729.
51. Yang, D.R.; Ding, X.F.; Luo, J.; Shan, Y.X.; Wang, R.; Lin, S.J.; Li, G.; Huang, C.K.; Zhu, J.; Chen, Y.; Lee, S.O.; Chang, C. Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer. J. Biol. Chem. 2013, 288 (23), 16476-16483.
52. Wang, D.; Zhu, H.; Zhu, Y.; Liu, Y.; Shen, H.; Yin, R.; Zhang, Z.; Su, Z. CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer. Acta Histochem. 2013, 115 (4), 349-356.
53. Yoshida, A.; Hsu, L.C.; Dave, V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 1992, 46 (4-5), 239-244.
54. van den Hoogen, C.; van der Horst, G.; Cheung, H.; Buijs, J.T.; Lippitt, J.M.; Guzman-Ramirez, N.; Hamdy, F.C.; Eaton, C.L.; Thalmann, G.N.; Cecchini, M.G.; Pelger, R.C.; van der Pluijm, G. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 2010, 70 (12), 5163-5173.
55. Nishikawa, S.; Konno, M.; Hamabe, A.; Hasegawa, S.; Kano, Y.; Ohta, K.; Fukusumi, T.; Sakai, D.; Kudo, T.; Haraguchi, N.; Satoh, T.; Takiguchi, S.; Mori, M.; Doki, Y.; Ishii, H. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int. J. Oncol. 2013, 42 (4), 1437-1442.
56. Liu, P.; Kumar, I.S.; Brown, S.; Kannappan, V.; Tawari, P.E.; Tang, J.Z.; Jiang, W.; Armesilla, A.L.; Darling, J.L.; Wang, W. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br. J. Cancer 2013, 109 (7), 1876-1885.
57. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Li, H.; Bhatia, B.; Tang, S.; Reilly, J.G.; Chandra, D.; Zhou, J.; Claypool, K.; Coghlan, L.; Tang, D.G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25 (12), 1696-1708.
58. Bisson, I.; Prowse, D.M. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009, 19 (6), 683-697.
59. Li, T.; Su, Y.; Mei, Y.; Leng, Q.; Leng, B.; Liu, Z.; Stass, S.A.; Jiang, F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest. 2010, 90 (2), 234-244.
60. Rajasekhar, V.K.; Studer, L.; Gerald, W.; Socci, N.D.; Scher, H.I. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat. Commun. 2011, 2, 162.
61. Bae, K.M.; Parker, N.N.; Dai, Y.; Vieweg, J.; Siemann, D.W. Ecadherin plasticity in prostate cancer stem cell invasion. Am. J. Cancer Res. 2011, 1 (1), 71-84.
62. Liu, T.; Xu, F.; Du, X.; Lai, D.; Liu, T.; Zhao, Y.; Huang, Q.; Jiang, L.; Huang, W.; Cheng, W.; Liu, Z. Establishment and characterization of multi-drug resistant, prostate carcinomainitiating stem-like cells from human prostate cancer cell lines 22RV1. Mol. Cell Biochem. 2010, 340 (1-2), 265-273.
63. Zhang, L.; Jiao, M.; Li, L.; Wu, D.; Wu, K.; Li, X.; Zhu, G.; Dang, Q.; Wang, X.; Hsieh, J.T.; He, D. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J. Cancer Res. Clin. Oncol. 2012, 138 (4), 675-686.
64. Visvader, J.E.; Lindeman, G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10 (6), 717-728.
65. Daley, G.Q. Common themes of dedifferentiation in somatic cell reprogramming and cancer. Cold Spring Harb. Symp. Quant. Biol. 2008, 73, 171-174.
66. Park, I.H.; Zhao, R.; West, J.A.; Yabuuchi, A.; Huo, H.; Ince, T.A.; Lerou, P.H.; Lensch, M.W.; Daley, G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451 (7175), 141-146.
67. Moad, M.; Pal, D.; Hepburn, A.C.; Williamson, S.C.; Wilson, L.; Lako, M.; Armstrong, L.; Hayward, S.W.; Franco, O.E.; Cates, J.M.; Fordham, S.E.; Przyborski, S.; Carr-Wilkinson, J.; Robson, C.N.; Heer, R. A novel model of urinary tract differentiation, tissue regeneration, and disease: Reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur. Urol. 2013, 64 (5), 753-761.
68. Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, R.; Slukvin, II; Thomson, J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318 (5858), 1917-1920.
69. Loh, Y.H.; Wu, Q.; Chew, J.L.; Vega, V.B.; Zhang, W.; Chen, X.; Bourque, G.; George, J.; Leong, B.; Liu, J.; Wong, K.Y.; Sung, K.W.; Lee, C.W.; Zhao, X.D.; Chiu, K.P.; Lipovich, L.; Kuznetsov, V.A.; Robson, P.; Stanton, L.W.; Wei, C.L.; Ruan, Y.; Lim, B.; Ng, H.H. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 2006, 38 (4), 431-440.
70. Boyer, L.A.; Lee, T.I.; Cole, M.F.; Johnstone, S.E.; Levine, S.S.; Zucker, J.P.; Guenther, M.G.; Kumar, R.M.; Murray, H.L.; Jenner, R.G.; Gifford, D.K.; Melton, D.A.; Jaenisch, R.; Young, R.A. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122 (6), 947-956.
71. Lin, Y.; Yang, Y.; Li, W.; Chen, Q.; Li, J.; Pan, X.; Zhou, L.; Liu, C.; Chen, C.; He, J.; Cao, H.; Yao, H.; Zheng, L.; Xu, X.; Xia, Z.; Ren, J.; Xiao, L.; Li, L.; Shen, B.; Zhou, H.; Wang, Y.J. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol. Cell 2012, 48 (4), 627-640.
72. Rodriguez-Pinilla, S.M.; Sarrio, D.; Moreno-Bueno, G.; Rodriguez- Gil, Y.; Martinez, M.A.; Hernandez, L.; Hardisson, D.; Reis-Filho, J.S.; Palacios, J. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod. Pathol. 2007, 20 (4), 474-481.
73. Noh, K.H.; Kim, B.W.; Song, K.H.; Cho, H.; Lee, Y.H.; Kim, J.H.; Chung, J.Y.; Kim, J.H.; Hewitt, S.M.; Seong, S.Y.; Mao, C.P.; Wu, T.C.; Kim, T.W. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J. Clin. Invest. 2012, 122 (11), 4077-4093.
74. Hochedlinger, K.; Yamada, Y.; Beard, C.; Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005, 121 (3), 465-477.
75. Linn, D.E.; Yang, X.; Sun, F.; Xie, Y.; Chen, H.; Jiang, R.; Chen, H.; Chumsri, S.; Burger, A.M.; Qiu, Y. A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells. Genes Cancer 2010, 1 (9), 908-916.
76. Tai, M.H.; Chang, C.C.; Kiupel, M.; Webster, J.D.; Olson, L.K.; Trosko, J.E. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005, 26 (2), 495-502.
77. de Resende, M.F.; Chinen, L.T.; Vieira, S.; Jampietro, J.; da Fonseca, F.P.; Vassallo, J.; Campos, L.C.; Guimaraes, G.C.; Soares, F.A.; Rocha, R.M. Prognostication of OCT4 isoform expression in prostate cancer. Tumour Biol. 2013, 34 (5), 2665-2673.
78. Robey, R.W.; Polgar, O.; Deeken, J.; To, K.W.; Bates, S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007, 26 (1), 39-57.
79. Dean, M.; Fojo, T.; Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5 (4), 275-284.
80. Ma, Y.; Liang, D.; Liu, J.; Axcrona, K.; Kvalheim, G.; Giercksky, K.E.; Nesland, J.M.; Suo, Z. Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumour Biol. 2012, 33 (4), 967-978.
81. Sims-Mourtada, J.; Izzo, J.G.; Ajani, J.; Chao, K.S. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007, 26 (38), 5674-5679.
82. Bhattacharya, S.; Das, A.; Mallya, K.; Ahmad, I. Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J. Cell Sci. 2007, 120 (Pt 15), 2652-2662.
83. Bleau, A.M.; Hambardzumyan, D.; Ozawa, T.; Fomchenko, E.I.; Huse, J.T.; Brennan, C.W.; Holland, E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4 (3), 226-235.
84. Bitting, R.L.; Armstrong, A.J. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr. Relat. Cancer 2013, 20 (3), R83-99.
85. Pourmand, G.; Ziaee, A.A.; Abedi, A.R.; Mehrsai, A.; Alavi, H.A.; Ahmadi, A.; Saadati, H.R. Role of PTEN gene in progression of prostate cancer. Urol. J. 2007, 4 (2), 95-100.
86. Taylor, B.S.; Schultz, N.; Hieronymus, H.; Gopalan, A.; Xiao, Y.; Carver, B.S.; Arora, V.K.; Kaushik, P.; Cerami, E.; Reva, B.; Antipin, Y.; Mitsiades, N.; Landers, T.; Dolgalev, I.; Major, J.E.; Wilson, M.; Socci, N.D.; Lash, A.E.; Heguy, A.; Eastham, J.A.; Scher, H.I.; Reuter, V.E.; Scardino, P.T.; Sander, C.; Sawyers, C.L.; Gerald, W.L. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18 (1), 11-22.
87. Martelli, A.M.; Evangelisti, C.; Chappell, W.; Abrams, S.L.; Basecke, J.; Stivala, F.; Donia, M.; Fagone, P.; Nicoletti, F.; Libra, M.; Ruvolo, V.; Ruvolo, P.; Kempf, C.R.; Steelman, L.S.; McCubrey, J.A. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011, 25 (7), 1064-1079.
88. Lim, M.; Chuong, C.M.; Roy-Burman, P., PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures. Horm. Cancer 2011, 2 (5), 298-309.
89. Mulholland, D.J.; Kobayashi, N.; Ruscetti, M.; Zhi, A.; Tran, L.M.; Huang, J.; Gleave, M.; Wu, H. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012, 72 (7), 1878-1889.
90. Lau, C.K.; Yang, Z.F.; Ho, D.W.; Ng, M.N.; Yeoh, G.C.; Poon, R.T.; Fan, S.T. An Akt/hypoxia-inducible factor-1alpha/plateletderived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin. Cancer Res. 2009, 15 (10), 3462-3471.
91. Lee, T.K.; Castilho, A.; Cheung, V.C.; Tang, K.H.; Ma, S.; Ng, I.O. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011, 53 (1), 160-170.
92. Ma, S.; Lee, T.K.; Zheng, B.J.; Chan, K.W.; Guan, X.Y., CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27 (12), 1749-1758.
93. Sharma, P.K.; Singh, R.; Novakovic, K.R.; Eaton, J.W.; Grizzle, W.E.; Singh, S. CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. Int. J. Cancer 2010, 127 (9), 2020-2030.
94. Kumar, D.; Shankar, S.; Srivastava, R.K. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/ Akt/mTOR signaling pathway. Cancer Lett. 2014, 343 (2), 179-189.
95. Di Cristofano, A.; Pandolfi, P.P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100 (4), 387-390.
96. Yilmaz, O.H.; Valdez, R.; Theisen, B.K.; Guo, W.; Ferguson, D.O.; Wu, H.; Morrison, S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441 (7092), 475-482.
97. Lee, J.T., Jr.; Steelman, L.S.; McCubrey, J.A. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004, 64 (22), 8397-8404.
98. Priulla, M.; Calastretti, A.; Bruno, P.; Azzariti, A.; Paradiso, A.; Canti, G.; Nicolin, A. Preferential chemosensitization of PTENmutated prostate cells by silencing the Akt kinase. Prostate 2007, 67 (7), 782-789.
99. Huang, H.; Cheville, J.C.; Pan, Y.; Roche, P.C.; Schmidt, L.J.; Tindall, D.J. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 2001, 276 (42), 38830-38836.
100. Morikawa, Y.; Koike, H.; Sekine, Y.; Matsui, H.; Shibata, Y.; Ito, K.; Suzuki, K. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation. Biochem. Biophys. Res. Commun. 2012, 419 (3), 584-589.
101. Yasumizu, Y.; Miyajima, A.; Kosaka, T.; Miyazaki, Y.; Kikuchi, E.; Oya, M. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J. Urol. 2014, 191 (1), 227-234.
102. Yu, X.; Wang, Y.; DeGraff, D.J.; Wills, M.L.; Matusik, R.J. Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2011, 30 (16), 1868-1879.
103. Hsieh, I.S.; Chang, K.C.; Tsai, Y.T.; Ke, J.Y.; Lu, P.J.; Lee, K.H.; Yeh, S.D.; Hong, T.M.; Chen, Y.L. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis 2013, 34 (3), 530-538.
104. Yang, W.; Yan, H.X.; Chen, L.; Liu, Q.; He, Y.Q.; Yu, L.X.; Zhang, S.H.; Huang, D.D.; Tang, L.; Kong, X.N.; Chen, C.; Liu, S.Q.; Wu, M.C.; Wang, H.Y. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008, 68 (11), 4287-4295.
105. Noda, T.; Nagano, H.; Takemasa, I.; Yoshioka, S.; Murakami, M.; Wada, H.; Kobayashi, S.; Marubashi, S.; Takeda, Y.; Dono, K.; Umeshita, K.; Matsuura, N.; Matsubara, K.; Doki, Y.; Mori, M.; Monden, M. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br. J. Cancer 2009, 100 (10), 1647-1658.
106. Flahaut, M.; Meier, R.; Coulon, A.; Nardou, K.A.; Niggli, F.K.; Martinet, D.; Beckmann, J.S.; Joseph, J.M.; Muhlethaler-Mottet, A.; Gross, N. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 2009, 28 (23), 2245-2256.
107. Chau, W.K.; Ip, C.K.; Mak, A.S.; Lai, H.C.; Wong, A.S. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 2013, 32 (22), 2767-2781.
108. Almeida, M.; Han, L.; Bellido, T.; Manolagas, S.C.; Kousteni, S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenindependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J. Biol. Chem. 2005, 280 (50), 41342-41351.
109. Liu, S.; Dontu, G.; Wicha, M.S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005, 7 (3), 86-95.
110. James, D.; Levine, A.J.; Besser, D.; Hemmati-Brivanlou, A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005, 132 (6), 1273-1282.
111. Lu, W.; Lin, C.; King, T.D.; Chen, H.; Reynolds, R.C.; Li, Y. Silibinin inhibits Wnt/beta-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal. 2012, 24 (12), 2291-2296.
112. Espinoza, I.; Pochampally, R.; Xing, F.; Watabe, K.; Miele, L. Notch signaling: targeting cancer stem cells and epithelial-tomesenchymal transition. Onco. Targets Ther. 2013, 6, 1249-1259.
113. Ranganathan, P.; Weaver, K.L.; Capobianco, A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11 (5), 338-351.
114. Zhu, H.; Zhou, X.; Redfield, S.; Lewin, J.; Miele, L. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am. J. Transl. Res. 2013, 5 (3), 368-378.
115. Wang, Z.; Li, Y.; Ahmad, A.; Banerjee, S.; Azmi, A.S.; Kong, D.; Wojewoda, C.; Miele, L.; Sarkar, F.H. Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J. Cell Biochem. 2011, 112 (1), 78-88.
116. Ye, Q.F.; Zhang, Y.C.; Peng, X.Q.; Long, Z.; Ming, Y.Z.; He, L.Y. siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. Asian Pac. J. Cancer Prev. 2012, 13 (6), 2485-2489.
117. Sarkar, F.H.; Li, Y.; Wang, Z.; Kong, D. Novel targets for prostate cancer chemoprevention. Endocr. Relat. Cancer 2010, 17 (3), R195-212.
118. Janikova, M.; Skarda, J. Differentiation pathways in carcinogenesis and in chemo- and radioresistance. Neoplasma 2012, 59 (1), 6-17.
119. Hutchin, M.E.; Kariapper, M.S.; Grachtchouk, M.; Wang, A.; Wei, L.; Cummings, D.; Liu, J.; Michael, L.E.; Glick, A.; Dlugosz, A.A. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005, 19 (2), 214-223.
120. Hatsell, S.; Frost, A.R. Hedgehog signaling in mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasia 2007, 12 (2-3), 163-173.
121. Mfopou, J.K.; Bouwens, L. Hedgehog signals in pancreatic differentiation from embryonic stem cells: revisiting the neglected. Differentiation 2008, 76 (2), 107-117.
122. Shaw, G.; Prowse, D.M. Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Cancer Cell Int. 2008, 8, 3.
123. Singh, S.; Chitkara, D.; Mehrazin, R.; Behrman, S.W.; Wake, R.W.; Mahato, R.I. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One 2012, 7 (6), e40021.
124. Chang, H.H.; Chen, B.Y.; Wu, C.Y.; Tsao, Z.J.; Chen, Y.Y.; Chang, C.P.; Yang, C.R.; Lin, D.P. Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model. J. Biomed. Sci. 2011, 18, 6.
125. Zhang, L.; Li, L.; Jiao, M.; Wu, D.; Wu, K.; Li, X.; Zhu, G.; Yang, L.; Wang, X.; Hsieh, J.T.; He, D. Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway. Cancer Lett. 2012, 323 (1), 48-57.
126. Crawford, T.Q.; Roelink, H. The notch response inhibitor DAPT enhances neuronal differentiation in embryonic stem cell-derived embryoid bodies independently of sonic hedgehog signaling. Dev. Dyn. 2007, 236 (3), 886-892.
127. Riobo, N.A.; Lu, K.; Ai, X.; Haines, G.M.; Emerson, C.P., Jr. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (12), 4505-4510.
128. Heiser, P.W.; Lau, J.; Taketo, M.M.; Herrera, P.L.; Hebrok, M. Stabilization of beta-catenin impacts pancreas growth. Development 2006, 133 (10), 2023-2032.
129. Yao, J.; An, Y.; Wie, J.S.; Ji, Z.L.; Lu, Z.P.; Wu, J.L.; Jiang, K.R.; Chen, P.; Xu, Z.K.; Miao, Y. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. Swiss Med. Wkly. 2011, 141, w13208.
130. Steg, A.D.; Bevis, K.S.; Katre, A.A.; Ziebarth, A.; Dobbin, Z.C.; Alvarez, R.D.; Zhang, K.; Conner, M.; Landen, C.N. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 2012, 18 (3), 869-881.
131. Perkins, N.D. The diverse and complex roles of NF-kappaB subunits in cancer. Nat. Rev. Cancer 2012, 12 (2), 121-132.
132. Codony-Servat, J.; Marin-Aguilera, M.; Visa, L.; Garcia-Albeniz, X.; Pineda, E.; Fernandez, P.L.; Filella, X.; Gascon, P.; Mellado, B. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate 2013, 73 (5), 512-521.
133. Kwon, O.; Kim, K.A.; Kim, S.O.; Ha, R.; Oh, W.K.; Kim, M.S.; Kim, H.S.; Kim, G.D.; Kim, J.W.; Jung, M.; Kim, C.H.; Ahn, J.S.; Kim, B.Y. NF-kappaB inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras-transformed human prostate epithelial cells. Carcinogenesis 2006, 27 (11), 2258-2268.
134. O'Neill, A.J.; Prencipe, M.; Dowling, C.; Fan, Y.; Mulrane, L.; Gallagher, W.M.; O'Connor, D.; O'Connor, R.; Devery, A.; Corcoran, C.; Rani, S.; O'Driscoll, L.; Fitzpatrick, J.M.; Watson, R.W. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol. Cancer 2011, 10, 126.
135. Syrovets, T.; Gschwend, J.E.; Buchele, B.; Laumonnier, Y.; Zugmaier, W.; Genze, F.; Simmet, T. Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgenindependent PC-3 prostate cancer cells in vitro and in vivo. J. Biol. Chem. 2005, 280 (7), 6170-6180.
136. Flynn, V., Jr.; Ramanitharan, A.; Moparty, K.; Davis, R.; Sikka, S.; Agrawal, K.C.; Abdel-Mageed, A.B. Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells. Int. J. Oncol. 2003, 23 (2), 317-323.
137. Lee, S.Y.; Cho, J.S.; Yuk, D.Y.; Moon, D.C.; Jung, J.K.; Yoo, H.S.; Lee, Y.M.; Han, S.B.; Oh, K.W.; Hong, J.T. Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. J. Pharmacol. Sci. 2009, 111 (2), 124-136.
138. Denmeade, S.R.; Isaacs, J.T. A history of prostate cancer treatment. Nat. Rev. Cancer 2002, 2 (5), 389-396.
139. Edwards, J.; Krishna, N.S.; Grigor, K.M.; Bartlett, J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 2003, 89 (3), 552-556.
140. Chen, C.D.; Welsbie, D.S.; Tran, C.; Baek, S.H.; Chen, R.; Vessella, R.; Rosenfeld, M.G.; Sawyers, C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10 (1), 33-39.
141. Taplin, M.E.; Rajeshkumar, B.; Halabi, S.; Werner, C.P.; Woda, B.A.; Picus, J.; Stadler, W.; Hayes, D.F.; Kantoff, P.W.; Vogelzang, N.J.; Small, E.J.; Cancer; Leukemia Group, B.S. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. Oncol. 2003, 21 (14), 2673-2678.
142. Debes, J.D.; Tindall, D.J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 2004, 351 (15), 1488-1490.
143. Jiao, J.; Hindoyan, A.; Wang, S.; Tran, L.M.; Goldstein, A.S.; Lawson, D.; Chen, D.; Li, Y.; Guo, C.; Zhang, B.; Fazli, L.; Gleave, M.; Witte, O.N.; Garraway, I.P.; Wu, H. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS One 2012, 7 (8), e42564.
144. Frank, N.Y.; Schatton, T.; Frank, M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120 (1), 41-50.
145. Fabian, A.; Barok, M.; Vereb, G.; Szollosi, J. Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry A 2009, 75 (1), 67-74.
146. Vidal, S.J.; Rodriguez-Bravo, V.; Galsky, M.; Cordon-Cardo, C.; Domingo-Domenech, J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2013, 1-13.
147. Zhou, Y.; Yang, J.; Kopecek, J. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials 2012, 33 (6), 1863-1872.
148. Shigdar, S.; Lin, J.; Yu, Y.; Pastuovic, M.; Wei, M.; Duan, W., RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011, 102 (5), 991-998.
149. Baeuerle, P.A.; Gires, O. EpCAM (CD326) finding its role in cancer. Br. J. Cancer 2007, 96 (3), 417-423.
150. Tang, D.G. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012, 22 (3), 457-472.
151. Kelly, P.N.; Dakic, A.; Adams, J.M.; Nutt, S.L.; Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317 (5836), 337.
152. Schatton, T.; Murphy, G.F.; Frank, N.Y.; Yamaura, K.; Waaga- Gasser, A.M.; Gasser, M.; Zhan, Q.; Jordan, S.; Duncan, L.M.; Weishaupt, C.; Fuhlbrigge, R.C.; Kupper, T.S.; Sayegh, M.H.; Frank, M.H. Identification of cells initiating human melanomas. Nature 2008, 451 (7176), 345-349.
153. Quintana, E.; Shackleton, M.; Sabel, M.S.; Fullen, D.R.; Johnson, T.M.; Morrison, S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456 (7222), 593-598.
154. Pienta, K.J.; Abate-Shen, C.; Agus, D.B.; Attar, R.M.; Chung, L.W.; Greenberg, N.M.; Hahn, W.C.; Isaacs, J.T.; Navone, N.M.; Peehl, D.M.; Simons, J.W.; Solit, D.B.; Soule, H.R.; VanDyke, T.A.; Weber, M.J.; Wu, L.; Vessella, R.L. The current state of preclinical prostate cancer animal models. Prostate 2008, 68 (6), 629-639.
155. Liu, Z.; Turkoz, A.; Jackson, E.N.; Corbo, J.C.; Engelbach, J.A.; Garbow, J.R.; Piwnica-Worms, D.R.; Kopan, R. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J. Clin. Invest. 2011, 121, (2), 800-808.